Pharmaceuticals, Biotechnology and Life Sciences
In a descriptive analysis, addition of Empliciti to pomalidomide and dexamethasone reduced risk of death by 46% among patients with…
DUBLIN–(BUSINESS WIRE)–The “Global Epidermolysis Bullosa Clinical Trial Pipeline Highlights, 2019” report has been added to ResearchAndMarkets.com’s offering. This report provides…
DUBLIN–(BUSINESS WIRE)–The “Global Peripheral Neuropathy Clinical Trial Pipeline Highlights, 2019” report has been added to ResearchAndMarkets.com’s offering. This report provides…
DUBLIN–(BUSINESS WIRE)–The “Global Post-Herpetic Neuralgia Clinical Trial Pipeline Highlights, 2019” report has been added to ResearchAndMarkets.com’s offering. This report provides…
DUBLIN–(BUSINESS WIRE)–The “Global Vasculitis Clinical Trial Pipeline Highlights, 2019” report has been added to ResearchAndMarkets.com’s offering. This report provides most…
DUBLIN–(BUSINESS WIRE)–The “Global Prader-Willi Syndrome Clinical Trial Pipeline Highlights, 2019” report has been added to ResearchAndMarkets.com’s offering. This report provides…
– ULTOMIRIS demonstrated consistent efficacy and safety through 52 weeks, with no cases of breakthrough hemolysis (BTH) associated with incomplete…
DUBLIN–(BUSINESS WIRE)–The “Pancreatitis – Global Clinical Trial Pipeline Highlights, 2019” report has been added to ResearchAndMarkets.com’s offering. This report provides…
DUBLIN–(BUSINESS WIRE)–The “Gonorrhea – Global Clinical Trial Pipeline Highlights, 2019” report has been added to ResearchAndMarkets.com’s offering. This report provides…
DUBLIN–(BUSINESS WIRE)–The “Zika Virus – Global Clinical Trial Pipeline Highlights, 2019” report has been added to ResearchAndMarkets.com’s offering. This report…